Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.43 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.43 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.35 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.35 |
| ▸ | KRAS | P01116 | 5/20 | 0.33 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.32 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19502504 | 0.88 | KDM4E (0.40) | KDM4ETAS1R3TAS1R1IMPDH2IMPDH1 | |
| SCHEMBL21073930 | 0.86 | KDM4E (0.38) | KDM4ETAS1R3TAS1R1IMPDH2IMPDH1 | |
| SCHEMBL17066101 | 0.85 | TAS1R3 (0.46) | KDM4ETAS1R3TAS1R1IMPDH2IMPDH1 | |
| SCHEMBL31430099 | 0.85 | TAS1R3 (0.43) | KDM4ETAS1R3TAS1R1IMPDH2IMPDH1 | |
| SCHEMBL19762769 | 0.85 | KDM4E (0.38) | KDM4ETAS1R3TAS1R1 | |
| SCHEMBL21073932 | 0.84 | KDM4E (0.38) | KDM4ETAS1R3TAS1R1IMPDH2 | |
| SCHEMBL17317468 | 0.84 | KDM4E (0.45) | KDM4ETAS1R3TAS1R1IMPDH2IMPDH1 | |
| SCHEMBL22036671 | 0.84 | KDM4E (0.45) | KDM4ETAS1R3TAS1R1IMPDH2IMPDH1 | |
| SCHEMBL18992534 | 0.83 | KDM4E (0.52) | KDM4ETAS1R3TAS1R1IMPDH2IMPDH1 | |
| SCHEMBL22434942 | 0.83 | KDM4E (0.52) | KDM4ETAS1R3TAS1R1IMPDH2IMPDH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210139604-A1 | COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | OPI VI - IP HOLDCO LLC | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139604-A1 | COMPOSITIONS OF ANTIBODY CONSTRUCT-AGONIST CONJUGATES AND METHODS OF USE THEREOF | STING1, CGAS, TLR7 | KDM4E 3375/4885TAS1R3 1381/4885TAS1R1 1315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.